arpa-h

The US government's health research agency has funded the first large-scale clinical trials testing whether rapamycin, semaglutide, and other repurposed drugs can slow biological aging in healthy adults, with results expected within three years.

ARPA-H has awarded up to $176.8 million to five teams building 3D-bioprinted kidneys and livers designed to work without immunosuppressive drugs, targeting first-in-human trials within five years.